Recurrence of the disease is the major problem in the treatment of acute myeloid leukemia (AML). The majority of patients who achieve a second remission will ultimately relapse. In this retrospective single-center study, we have analyzed the outcome of patients with a second relapse and tried to define the prognostic factors in intensively treated patients. Of 534 patients with AML, 62 had a second relapse. Thirty-three received further intensive chemotherapy (CT). Eighteen patients (55%) achieved a third complete remission (CR). The early death (ED) rate was only 9%. The overall survival (OS) of treated vs untreated patients was 6.9 vs 1.3 months, respectively (P = 0.01). The major selection criteria for a third CT were a favourable (t(15;17),t(8;21),inv(16)) or normal karyotype, long (Ͼ11 months) second CR (P р 0.005) and no previous bone marrow transplantation (BMT)(P Ͻ 0.01). Favorable or normal karyotype, second CR Ͼ11 months, as well as no previous BMT (P Ͻ 0.01) were associated with the achievement of a third CR. Favorable (P Ͻ 0.005) or normal karyotype (P Ͻ 0.01), as well as a second CR Ͼ11 months (P Ͻ 0.005) were associated with prolonged survival after CT. The median OS for patients receiving CT with favorable or normal cytogenetics, a second CR Ͼ 11 months, but no previous BMT was 26.5 months. Five patients with favorable or normal karyotype achieved a fourth or fifth remission. We conclude that intensive CT is associated with a survival benefit and good quality of life if patients are properly selected.
Introduction
With modern consolidation treatment about 60-80% of younger and 20-30% of older patients with de novo acute myeloid leukemia (AML) who achieve a first hematological remission enjoy a long-term remission and are possibly cured. 1, 2 Patients who relapse after chemotherapy (CT) have a definite chance to achieve a second remission after treatment with intensive CT. [3] [4] [5] We and others 6, 7 have shown that the probability of a second CR depends mainly on the duration of the first remission. About 20 to 30% of younger patients with a second remission can be cured by allogeneic stem cell transplantation, but only a few (about 10%) by CT alone. 1, 2, 8, 9 Thus, the vast majority of patients with a second remission will have a second relapse. The physician caring for such patients is faced with the problem that no data exist as to the risks and possible benefits of an intensive salvage CT. Therefore, we have analyzed the outcome of patients with a second relapse who were treated with intensive CT or only supportive care and tried to define the prognostic factors in intensively treated patients. 
Patients and methods
A total of 534 patients with the diagnosis of AML were admitted to our institution from 1979 to 1999. Of those patients, 497 were treated with intensive CT, 317/497 (64%) achieved a CR, which lasted for a median time of 8.24 months. Of 317, 196 (62%) patients relapsed. Of these 196 patients, 133 were again treated with CT and 82/133 (62%) achieved a second remission, which had a median duration of 6.6 months. Of 82 patients, 62 in second CR had a second relapse, 33 of those 62 patients underwent a third induction CT. Overall, 108/497 (22%) of patients initially treated underwent autologous or allogeneic bone marrow transplantation in the course of their disease.
AML was classified according to the FAB criteria. 10 Karyotypes were available in 59 patients. Immunophenotypic analysis was performed according to standard methods. [11] [12] [13] [14] For induction CT, the following chemotherapeutic regimens 
Statistical analysis
The Kaplan-Meier technique 19 was used to analyze the probability of overall survival (OS) and continuous complete remission (CCR). Survival was calculated from the time of second relapse until relapse or death from any cause, CCR from the time of CR3 until relapse. For the Kaplan-Meier analysis, all patients including those with BMT were considered. Statistical analysis were performed using parametric (Student's t-test) or non-parametric tests (Mann-Whitney rank sum test) on the basis of distribution of the data. Differences between means were considered as significant at P Ͻ 0.05. Data analysis was performed using WinStat for Windows (1996 Version 3.0, G Greulich Software, Germany).
Results

Demographic and hematological characteristics of patients with a second relapse
Sixty-two patients with de novo AML had a second relapse. The median age of these patients was 48 years (range 16-72) ( Table 1 , lane 1). Forty-six patients had received only CT prior to the second relapse and 16 patients (25%) had undergone either autologous (n = 9) or allogeneic BMT (n = 7). Of those, 15 had BMT in CCR after first relapse, and one received the BMT as third consolidation therapy. About one quarter of the patients (29%) had a favorable karyotype (inv(16) (n = 9), t(8;21) (n = 5) or t(15;17) (n = 2)) and another 25% (n = 16) a normal karyotype.
Selection of patients for CT
Thirty-three out of 62 patients received intensive reinduction treatment based on the individual decision of the treating physician. Twenty-one received the DAV or 3+7 protocol, two patients with FAB-M3 the AIDA protocol, eight patients the FLAG protocol and two patients the MIDAC regimen. Twentynine patients received either supportive treatment only or myelosuppressive treatment with hydroxyurea. There was no difference in the age of the patients who were treated or not (Table 1 , lanes 2 and 3). The major difference between intensively treated or patients receiving palliative treatment were a favorable or normal karyotype (23/32) compared to other aberrations (10/30) (P Ͻ 0.005), longer duration of the second CR (11 months vs 5.2 months; P р 0.005) and no previous bone marrow transplantation (29/46 pretreated with CT, 4/16 after BMT; P р 0.01). All patients treated had an ECOG performance status Ͻ2. The median interval from diagnosis of a second relapse to the start of treatment was 6 days (range 1-49 days). The reasons for only supportive therapy were either a low performance status (n = 19), short CR after BMT (n = 6) or patients simply refusing further chemotherapy.
Treatment results
Eighteen out of 33 patients (55%) treated with intensive chemotherapy achieved a third CR (Table 1 , lane 4). Three patients (9%) died from chemotherapy-related complications and 12 patients (36%) survived but did not achieve a third remission. Sixty-one percent of the patients with a favorable karyotype and 80% with a normal karyotype achieved a CR, in contrast to only 20% of those with complex aberrations (favorable + normal vs complex: P р 0.01). Thirteen of 18 patients who achieved a CR had a duration of their second CR of more than 11 months compared to only four of the 15 other patients (P р 0.01). Eighteen of 29 patients who had only received chemotherapy before second relapse, but none of the four patients who had a history of bone marrow transplantation achieved a third complete remission (P Ͻ 0.01).
Overall survival, disease-free survival and continuous complete remission
The median OS of all patients with a second relapse was 6.6 months (range 0.1-86+). The median OS of patients who were intensively treated was significantly longer than that of patients who received only palliative treatment (6.9 months 2061 vs 1.3 months, P = 0.01, Figure 1 ). The median CCR of the 18 patients achieving a third CR was 14.7 months (not shown). Figure 2 shows that patients with a favorable or normal karyotype had a longer survival when treated with intensive CT, while those with complex aberrations had no benefit. The other factor which was significantly associated with prolonged survival after CT was a second CR of more than 11 months (median OS 10.7 months; P Ͻ 0.005) (Figure 3 ). The median OS of patients who had no previous BMT, but favorable or normal cytogenetics and a second CR Ͼ11 months was 26.5 months (not shown). The only patient with a longterm third remission is an elderly female with promyelocytic leukemia who received maintenance therapy with ATRA according to the French protocol after the third remission.
Patients with multiple relapses and remissions
There is a small group (n = 5) of patients who showed a peculiar response to treatment. They had multiple relapses but achieved a fourth or even a fifth complete remission with intensive chemotherapy (Figure 4) . These patients had a favorable or normal karyotype and older age (median 61 years). One interesting phenomenon in this group was the fact that the duration of the third remission was almost equal and in two cases (patient Nos 3 and 5) even longer than previous remissions. One patient is still alive in fourth complete remission, two patients died in fourth or fifth complete remission and two patients were refractory to treatment after the fourth or fifth relapse.
Discussion
Among 534 patients with de novo AML who were initially treated in our center, 62 (12%) had a second relapse. One half of these patients were considered for further intensive CT. There were no predetermined rules which patients should be treated intensively. The decision was made after extensive discussion with the patient considering the presumed risks and chances of treatment. The retrospective analysis of these factors which have determined the decision showed that, surprisingly, age was no limiting factor. 20 The probability of treatment was higher in patients with a favorable or normal karyotype and with a longer second remission. 6, 7 In our study, nine patients were classified as AML with abnormal bone mar-
Figure 1
OS of treated (third CT) vs untreated (without third CT) patients with second relapse.
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Figure 2
OS of treated (third CT) vs untreated (without third CT) patients with second relapse according to karyotype. Patients (a) with favorable, (b) with normal karyotype or (c) with complex aberrations. row eosinophils and inv(16)(p13;q22) according to the WHO classification, five as AML t(8;21)(q22;q22) and two as acute promyelocytic leukaemia (AML with t (15;17) ). 21 The majority of these patients were considered for further chemotherapy and contributed to the high response rates as expected. Patients who relapsed after bone marrow transplantation were less likely to be retreated. Of note, only two of the 12 transplant patients who were not treated had recovered in their hemopoiesis, while the four patients treated had a trilineage recovery after transplantation. OS of patients treated with CT: second CR Ͼ11 months vs р11 months.
Figure 4
Course of disease of five patients with three or more relapses and remissions. Black arrows indicate courses of chemotherapy, white boxes time in complete remission, black boxes time of no remission. Time is given in months.
Half of the intensively treated patients achieved a third remission. Interestingly, the death rate during chemotherapy was only 9% which is low, considering the advanced stage of the disease and the older age of the patients. It certainly reflects the efficient selection of patients who were considered as fit for retreatment.
The survival of patients who were intensively treated was significantly longer than that of patients who received only palliative treatment. The major factors influencing survival were again favorable or normal cytogenetics and long duration of the second CR. Patients with both of these beneficial factors and without previous BMT had a probability of survival of more than 2 years. Although, patients who underwent CT had a survival benefit with good quality of life it should be emphasized that these data and conclusions are not based on the results of a randomized trial and must therefore be interpreted with caution. It cannot be excluded that patients who were intensively treated would have also done better with supportive treatment. 22, 23 All patients except one who achieved a third remission ultimately relapsed, but in a few a fourth or fifth remission could be achieved. This latter group includes five patients characterized by advanced age, M2 or M4 morphology and a favorable or normal karyotype. They all had a first remission duration exceeding 12 months, but with one exception the duration of the first remission was not particularly long. Unexpectedly, the well-known rule that subsequent remissions are considerably shorter than the preceding remissions did not apply to these patients, since the duration of the subsequent remissions was approximately in the same range.
In summary, our data show that patients with a second relapse of AML have a reasonable chance of achieving a third remission after intensive chemotherapy, if properly selected. It remains to be established if the selection criteria will also apply to novel therapies like non-myeloablative stem cell transplantation. 24 
